Clinical trials: Pregnancy, Ovarian
Menopause, Premature
Impact of Treatment Induced Premature Menopause on Quality of Life
To understand the impact of treatment induced menopause on quality of life and sexuality following blood and marrow transplantation.
- Trial name
- NCT00185718
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Stanford University
Dysfunction; Endocrine, Effects of Chemotherapy
Blood Spot Self-administered Test and Assay
The current study will compare hormone levels of AMH, FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of pre-menopausal women ages 18-45 years with normal menstrual cycles.
- Conditions
- Dysfunction; Endocrine, Effects of Chemotherapy, Premature Ovarian Failure
- Trial name
- NCT03840824
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Ovarian Cancer
Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
The purpose of this study is to study efficacy and the effects on quality of life in women with ovarian cancer treated with a weekly schedule of chemotherapy with carboplatin and paclitaxel compared to those treated with standard…
- Trial name
- MITO-7 (NCT00660842)
- Testing
- carboplatin, paclitaxel
- Where
- 28 sites in Italy
- Volunteers
- 800 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer, Ovarian Carcinoma
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer
- Trial name
- NCT03748186
- Testing
- STRO-002
- Where
- 27 sites in United States, Spain
- Volunteers
- 136 people
- Sponsor
- Sutro Biopharma, Inc.
Ovarian Neoplasms
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment.
- Trial name
- NCT06242392
- Testing
- homologous recombination deficiency
- Volunteers
- 250 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Hyperstimulation Syndrome
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
- Trial name
- NCT00329693
- Testing
- Norprolac
- Where
- 7 sites in Spain
- Volunteers
- 182 people
- Sponsor
- Ferring Pharmaceuticals
Cancer
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
RATIONALE: Donor mesenchymal stem cell infusion may be an effective treatment for acute or chronic graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00361049
- Testing
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01610206
- Testing
- Gemcitabine, pazopanib
- Where
- 8 sites in United States
- Volunteers
- 148 people
- Sponsor
- Linda R Duska
Infertility, Polycystic Ovarian Syndrome
Letrozole Versus Clomifene Citrate for Ovulation Induction
The primary aim of the study is to assess the efficacy of letrozole as an ovulation induction agent and to test the hypothesis that letrozole will generate better pregnancy rates with fewer multiple pregnancies and higher live…
- Trial name
- NCT00478504
- Testing
- Letrozole, Clomifene citrate
- Where
- United Kingdom
- Volunteers
- 159 people
- Sponsor
- University of Nottingham
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Lung Adenocarcinoma, Ovarian Cancer
CAR T Cells in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
- Conditions
- Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03054298
- Testing
- huCART-meso cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pennsylvania
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Subfertility
DHEA Versus Placebo in Women With Poor Ovarian Response
440 women with expected poor ovarian response undergoing IVF/ICSI (intracytoplasmic sperm injection) will be randomly divided into 2 groups using computer generated random numbers .
- Trial name
- DHEA (NCT02561793)
- Testing
- DHEA
- Where
- 2 sites in Egypt
- Volunteers
- 440 people
- Sponsor
- Cairo University
Ovarian Cancer
A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer
A study to discuss the advantage of Fapi PET- CT in the initial diagnosis staging and lesion determination of ovarian cancer,whether it can be a evaluation strategy as an R0 evaluation tool or a prediction tool of chemotherapy…
- Trial name
- NCT05824247
- Testing
- 68Ga-FAPI-PET-CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Polycystic Ovary Syndrome
Study of Metabolism and Cardiovascular Disease(CVD) in Women With Polycystic Ovary Syndrome (PCOS)
PCOS is the most common endocrine disorder in reproductive women. It is estimated that 5 to 10% of women of reproductive age have PCOS.
- Trial name
- NCT01117558
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Ovarian Cancer
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery.
- Trial name
- MITO 35B (NCT05255471)
- Testing
- Olaparib, Chemotherapy drug
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Fallopian Tube Cancer, Ovarian Cancer
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- S0009 (NCT00008138)
- Testing
- carboplatin, paclitaxel, debulking surgery
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Surgical Menopause, BRCA1 Mutation
Health After eaRly Menopause Due to Oophorectomy
Risk-Reducing Salpingo-Oophorectomy (RRSO) at the age of 35 to 45 years is recommended for women with a high genetic risk for ovarian cancer.
- Conditions
- Surgical Menopause, BRCA1 Mutation, BRCA2 Mutation, Cardiovascular Diseases
- Trial name
- HARMOny (NCT03835793)
- Testing
- CAC-score
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- The Netherlands Cancer Institute
Ovarian Neoplasms
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass
Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine…
- Trial name
- NCT06566716
- Testing
- CleoDX ovarian cancer test
- Where
- 19 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleo Diagnostics Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.